Trial Profile
A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel), Followed by a Single-Arm, Open-Label Phase of Subcutaneously Administered Neugranin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Balugrastim (Primary) ; Pegfilgrastim
- Indications Neutropenia
- Focus Registrational; Therapeutic Use
- Acronyms NEUGR-003
- Sponsors Teva Branded Pharmaceutical Products R&D
- 30 Sep 2014 New trial record